Bioasis Technologies (FRA:107) Interest Expense : €-0.69 Mil (TTM As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Bioasis Technologies Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Bioasis Technologies's interest expense for the three months ended in Nov. 2022 was € -0.16 Mil. Its interest expense for the trailing twelve months (TTM) ended in Nov. 2022 was €-0.69 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Bioasis Technologies's Operating Income for the three months ended in Nov. 2022 was € -0.51 Mil. Bioasis Technologies's Interest Expense for the three months ended in Nov. 2022 was € -0.16 Mil. Bioasis Technologies did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Bioasis Technologies Interest Expense Historical Data

The historical data trend for Bioasis Technologies's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies Interest Expense Chart

Bioasis Technologies Annual Data

Trend

Feb13

Feb14

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Interest Expense

Get a 7-Day Free Trial

-0.03

-0.09

-0.45

Bioasis Technologies Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
Interest Expense	Get a 7-Day Free Trial															-0.17	-0.18	-0.18	-0.18	-0.16

Bioasis Technologies Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Nov. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.69 Mil.

Bioasis Technologies (FRA:107) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Bioasis Technologies's Interest Expense for the three months ended in Nov. 2022 was €-0.16 Mil. Its Operating Income for the three months ended in Nov. 2022 was €-0.51 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Nov. 2022 was €0.52 Mil.

Bioasis Technologies's Interest Coverage for the quarter that ended in Nov. 2022 is calculated as

Bioasis Technologies did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Bioasis Technologies (FRA:107) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (FRA:107) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

157 Church Street, 19th Floor, New Haven, CT, USA, 06510

Website

https://www.bioasis.us

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies (FRA:107) Headlines

No Headlines